Research and Development

Pipeline

The group's most advanced programme, a potential anti-inflammatory treatment for COPD, has recently entered a Phase IIa proof of concept clinical trial. The development candidate, known as ADC4022, is a proprietary combination approach to render COPD and steroid insensitive asthma responsive to steroid therapies. The group owns all rights to this programme.

Argenta's pre-clinical programmes, all of which are expected to be in the clinic by 2008/9, include:

• An inhaled anti-inflammatory for the treatment of COPD. We have identified and selected candidates for development for inhaled administration from a well-understood class of drugs (partnered with Dr Reddy's)
• Inhaled long-acting muscarinic (M3) receptor antagonists (LAMA) (partnered with AstraZeneca)
• Inhaled dual-acting muscarinic (M3) receptor antagonists / beta-2 receptor agonists (MABA) (partnered with AstraZeneca)
• Inhaled single domain antibody (dAb) anti-inflammatory (partnered with Domantis, a subsidiary of GlaxoSmithKline)
• Inhaled elastase inhibitors, believed to be the first small molecules in their class for the treatment of CF and COPD
• Oral prostaglandin D2 (CRTh2) receptor antagonists for the treatment of allergic asthma and rhinitis

For more information about collaboration opportunities in our respiratory programmes please contact us.

We are developing innovative therapies for COPD, Asthma and CF.

Download pipeline graphic (PDF)